FDA Approves New Targeted Combo Therapy for Melanoma

Survival advantages are unprecedented, says expert. Encorafenib and binimetinib are a late-stage BRAF and MEK inhibitor combination for metastatic disease.
FDA Approvals

https://ift.tt/2MufXeu